TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05219760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIVIA
Description: The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIVIA
Description: The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance.
Study: NCT05002231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg oral tablet
Description: Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod two 7.5 mg oral tablets
Description: Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod one 15 mg oral tablet
Description: Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
Study: NCT05234294

Intervention type: OTHER
Intervention: Survey
Description: We will investigate symptoms through monthly surveys.

Intervention type: OTHER
Intervention: Survey
Description: We will investigate symptoms through monthly surveys.
Study: NCT06190873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-discharge rehabilitation training
Description: Telephone training will be provided for post-discharge rehabilitation
Study: NCT05296369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid was added during the period prior to concurrent chemoradiotherapy
Study: NCT05210998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual Aerobic exercise training AND Respiratory muscle training
Description: Combined Exercise Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual Aerobic exercise training
Description: Aerobic exercise Group
Study: NCT04668118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol
Description: As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
Study: NCT06457009

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multi-component Intervention Package
Description: 1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners.
Study: NCT06540365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways and Resources for Engagement and Participation (PREP)
Description: Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
Study: NCT04926740

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Description: Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
Study: NCT04973839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)
Description: Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)
Description: Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)
Description: Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)
Description: Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
Study: NCT04934332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound examination at 1 week and 5 weeks after admission.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Weekly clinical examination from week-2 to week-5.
Study: NCT05349032

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Curcumin
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Curcumin
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Curcumin
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Curcumin
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Curcumin
Description: Oral supplement
Study: NCT05602974

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: adjuvant stereotactic body radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular follow-up
Description: regular follow-up
Study: NCT05055778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmokefreeTXT
Description: The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings.
Study: NCT06359418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
Study: NCT05446480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
Study: NCT04754321

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation Therapy
Description: Undergo IORT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation Therapy
Description: Undergo IORT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation Therapy
Description: Undergo IORT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage Surgery
Description: Undergo salvage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage Surgery
Description: Undergo salvage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage Surgery
Description: Undergo salvage surgery
Study: NCT06539988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Coaching Sessions
Description: PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized text messages to patients
Description: Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
Study: NCT05811260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release technique
Description: on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post facilitation stretch .
Description: static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
Study: NCT05829473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise Group
Description: A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery Group
Description: 10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
Study: NCT05558852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Meshless Sacrocolpopexy Technique
Description: Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
Study: NCT06518720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
Study: NCT05563584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Rehab
Description: A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
Study: NCT06516393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The radial shock wave device
Description: The r-ESWT+Kinesio Tape Application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The radial shock wave device
Description: The r-ESWT+Kinesio Tape Application
Study: NCT04172779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Oral administration of erlotinib 25mg tablet
Study: NCT04638725

Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
Study: NCT05068180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose neuroleptanalgesia
Description: Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
Study: NCT06574854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSW
Description: Descending Stair Walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASW
Description: Ascending Stair Walking
Study: NCT05584618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: education
Study: NCT05915247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HER-096
Description: Administered as a single dose via s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HER-096
Description: Administered as a single dose via s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single dose via s.c. injection
Study: NCT04814381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + Magnesium sulfate (drug combination)
Description: A single infusion will be performed over 2 hours with 90 days follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Magnesium sulfate (drug combination)
Description: A single infusion will be performed over 2 hours with 90 days follow-up.
Study: NCT04983472

Intervention type: OTHER
Intervention: Observational
Description: Respiratory muscle electromyographic activations of individuals will be taken during supine, normal sitting and dyspnea reduction positions. Individuals with chronic obstructive pulmonary disease will be asked to perform normal breathing, pursed lip breathing, and breathing control during these positions. Respiratory muscle activation measurement of individuals will be taken during different breathing patterns in each position. Respiratory functions will be evaluated with pulmonary function test, respiratory muscle strength, intraoral pressure measurement device, respiratory muscle activation with surface electromyographic device, health status disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
Study: NCT05003167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST-150)
Description: All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
Study: NCT04987307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study: NCT04735510

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion 0.05%
Description: All subjects will receive restasis